The shares of OrganiGram Holdings Inc. (NASDAQ:OGI) has been pegged with a rating of Outperform by Raymond James in its latest research note that was published on January 15, 2020. Raymond James wasn’t the only research firm that published a report of OrganiGram Holdings Inc., with other equities research analysts also giving their opinion on the stock. The stock had earned Mkt Perform rating from Raymond James Markets when it published its report on January 09, 2020. Cantor Fitzgerald was of a view that OGI is Overweight in its latest report on November 05, 2019. Jefferies thinks that OGI is worth Buy rating.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 4 believe it has the potential for further growth, thus rating it as Hold while 9 advised investors to purchase the stock. The consensus currently stands at a Overweight while its average price target is $4.85. The price of the stock the last time has raised by 25.53% from its 52-Week high price while it is -79.03% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 44.29.
The shares of the company added by 8.59% during the trading session on Wednesday, reaching a low of $1.64 while ending the day at $1.77. During the trading session, a total of 4.36 million shares were traded which represents a 0.33% incline from the average session volume which is 4.37 million shares. OGI had ended its last session trading at $1.63. OGI 52-week low price stands at $1.41 while its 52-week high price is $8.44.
The company in its last quarterly report recorded -$0.02 earnings per share which is above the predicted by most analysts. The OrganiGram Holdings Inc. generated 25.68 million in revenue during the last quarter. OrganiGram Holdings Inc. has the potential to record 0.00 EPS for the current fiscal year, according to equities analysts.
Investment analysts at JP Morgan published a research note on October 29, 2019 where it informed investors and clients that PennantPark Investment Corporation (NASDAQ:PNNT) is now rated as Underweight. Their price target on the stock stands at $6. Compass Point also rated PNNT as Downgrade on May 03, 2019, with its price target of $7 suggesting that PNNT could surge by 64.36% from its current share price. Even though the stock has been trading at $2.20/share, analysts expect it to surge by 14.55% to reach $7.07/share. It started the day trading at $2.89 and traded between $2.25 and $2.52 throughout the trading session.
A look at its technical shows that PNNT’s 50-day SMA is 5.59 while its 200-day SMA stands at 6.14. The stock has a high of $7.19 for the year while the low is $1.76. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 806555.3 shorted shares, the short percentage went lower by -7.51%, as 745,983 OGI shares were shorted. The company’s P/E ratio currently sits at 5.97, while the P/B ratio is 0.29. The company’s average trading volume currently stands at 521.38K shares, which means that the short-interest ratio is just 1.55 days. Over the past seven days, the company moved, with its shift of 25.37%. Looking further, the stock has dropped -62.11% over the past 90 days while it lost -59.94% over the last six months.
Following these latest developments, around 2.54% of PennantPark Investment Corporation stocks are owned by institutional investors and hedge funds.